Child and Adolescent Psychopharmacology Made Simple, 4th Edition
Author: John D. Preston, PsyD, ABPP,John H. O'Neal, MD, Mary C. Talaga, RPh, PhD and Bret A. Moore, PsyD, ABPP
(Click author's name for bio)
Course Created: 2021
Practice Level: Intermediate
John D. Preston, PsyD, ABPP,John H. O'Neal, MD, Mary C. Talaga, RPh, PhD and Bret A. Moore, PsyD, ABPP
John D. Preston, PsyD, ABPP, is a licensed psychologist, and author or coauthor of twenty books. He is professor emeritus of psychology at Alliant International University, and has also served on the faculty of the UC Davis School of Medicine. He has lectured widely in the United States and abroad. He is the recipient of the Mental Health Association’s President’s Award for contributions to the mental health professions, and is a fellow of the American Psychological Association. John H. O’Neal, MD, is a board-certified psychiatrist who has been in private practice since 1977. He is past chief of the department of psychiatry at Sutter Community Hospital in Sacramento, CA. He is associate clinical professor of psychiatry at the UC Davis School of Medicine, and is a fellow of the American Psychiatric Association. He lectures on depression and psychopharmacology to mental health profes- sionals, employee assistance programs, and the public. O’Neal received his master’s in clinical psychology from Harvard University, and doctor of medicine from the University of Washington. Mary C. Talaga, RPh, PhD, has been a pharmacist for thirty-nine years, with specialization in psychiatric pharmacy and pharmacy admin- istration. She has extensive experience in health care, and has practiced in a variety of clinical settings. Over her career, she has contributed to the development of best practice guidelines, and has promoted collabora- tive care models. She has provided training and mentoring to health care professionals, and education to patients and consumers. Bret A. Moore, PsyD, ABPP, is a board-certified clinical and pre- scribing psychologist in San Antonio, TX. Over the past twelve years, he has taught graduate-level courses in clinical psychopharmacology for multiple universities and colleges. He is the recipient of the Educator of the Year award from the American Society for the Advancement of Pharmacotherapy, and is a fellow of the American Psychological Association.
4.5 out of 5.0, Based on: 3,621 reviews
In 2019, 13.6% of U.S. children and adolescents aged 5–17 years old received mental health treatment, which included counseling, therapy, and/or medication. A total of 8.4% of the same age group took prescription medication for their mental health (Zablotsky & Terlizzi, 2020). Psychiatric medications, however, are only appropriate for specific types of emotional distress. While psychopharmacological treatment has been implemented for children and adolescents for several decades, it is critical to recognize that young people may experience emotional suffering due to multiple factors, including poverty, discrimination, prenatal conditions, trauma, and/or neuropsychiatric disorders. It is likewise essential that mental health providers are familiar with the conditions under which it is appropriate to refer children and adolescents for psychiatric medication evaluations and treatment. The purpose of this course is to present an overview of clinical psychopharmacology for children and adolescents suffering from a range of mental health conditions, which include ADHD, depression, anxiety disorders, bipolar disorder, psychotic disorders, and other mental and behavioral disorders. This course provides social workers, psychologists, marriage and family therapists, and counselors with information on diagnostics, differential diagnosis, and medication strategies. The descriptions of psychopharmacology contained in the text offers mental health and human services providers the opportunity to update, improve, or gain the tools and knowledge base necessary for recognizing when clients are in need of psychiatric medication evaluation referrals, discussing the benefits and risks of psychopharmacology with patients and their parents, and supporting clients and parents with the treatments recommended by a child or teen’s prescriber, including over-the-counter (OTC) products.
This course is based on a book and a post test. When you're ready, purchase the test by clicking the "Add To Cart" button. This will let you take the test and receive your certificate for CE credits.
- Explain current issues in psychopharmacological treatment of children and adolescents.
- Discuss the treatment considerations for depression in children and adolescents.
- Distinguish the types, presentations, and treatments of bipolar disorder in young patients.
- Describe the symptoms of and treatment interventions for anxiety disorders in children and teens.
- Recognize symptoms of childhood psychotic disorders and the possible side effects of antipsychotic medications used to treat these disorders.
- Discuss diagnostic and treatment considerations for young patients presenting with attention-deficit/hyperactivity disorder (ADHD) symptoms.
- Recognize symptoms that may indicate autism spectrum disorder (ASD) and medications shown to improve associated symptoms of pervasive neurodevelopmental disorders (PDNs) in children and teens.
- Identify symptoms of and treatments for sleep disorders in children and adolescents.
- Explain psychological and physical concerns related to substance abuse, tics, and eating disorder treatments.
- Compare the risks and benefits of OTC treatments for depression and anxiety disorders.
CE4Less.com, provider #1115, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 07/08/21-07/08/24. Social workers completing this course will receive continuing education credit hours.
We are committed to providing our learners with unbiased information. Ce4Less never accepts commercial support and our authors have no significant financial or other conflicts of interest pertaining to the material.